Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (231-240 of 768) with videos related to

Pageof 77
Sort By:
Blood|April 1, 1991
Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantationL Ugozzoli, P Yam, L D Petz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphomaC Hosing, R M Saliba, P McLaughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2010
Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantationStefan O Ciurea, Victor Mulanovich, Ying Jiang, et al.
Bone Marrow Transplantation|May 1, 1996
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experienceI F Khouri, H M Kantarjian, M Talpaz, et al.
Bonekey Reports|December 27, 2016
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trialHuifang Lu, Richard E Champlin, Uday Popat, et al.
Blood Advances|July 30, 2020
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantationJun Zou, Stefan O Ciurea, Piyanuch Kongtim, et al.
Leukemia & Lymphoma|May 27, 2004
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myelomaMichele L Donato, Ana Aleman, Richard E Champlin, et al.
Bone Marrow Transplantation|June 7, 2005
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemiaC Hosing, R M Saliba, M Shahjahan, et al.
American Journal of Hematology|October 15, 2013
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemiaMichael J Eckrich, Kwang-Woo Ahn, Richard E Champlin, et al.
Leukemia & Lymphoma|May 22, 2014
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myelomaIsabella C Glitza, Gary Lu, Rupin Shah, et al.
Pageof 77

Showing results (231-240 of 768) with videos related to

Sort By:
Pageof 77
Blood|April 1, 1991
Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantationL Ugozzoli, P Yam, L D Petz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphomaC Hosing, R M Saliba, P McLaughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2010
Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantationStefan O Ciurea, Victor Mulanovich, Ying Jiang, et al.
Bone Marrow Transplantation|May 1, 1996
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experienceI F Khouri, H M Kantarjian, M Talpaz, et al.
Bonekey Reports|December 27, 2016
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trialHuifang Lu, Richard E Champlin, Uday Popat, et al.
Blood Advances|July 30, 2020
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantationJun Zou, Stefan O Ciurea, Piyanuch Kongtim, et al.
Leukemia & Lymphoma|May 27, 2004
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myelomaMichele L Donato, Ana Aleman, Richard E Champlin, et al.
Bone Marrow Transplantation|June 7, 2005
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemiaC Hosing, R M Saliba, M Shahjahan, et al.
American Journal of Hematology|October 15, 2013
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemiaMichael J Eckrich, Kwang-Woo Ahn, Richard E Champlin, et al.
Leukemia & Lymphoma|May 22, 2014
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myelomaIsabella C Glitza, Gary Lu, Rupin Shah, et al.
Pageof 77